• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease.肝硬化和非肝硬化非酒精性脂肪性肝病中肝细胞癌的特征
World J Gastroenterol. 2015 Jan 28;21(4):1189-96. doi: 10.3748/wjg.v21.i4.1189.
2
Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.非肝硬化非酒精性脂肪性肝病(NAFLD)患者肝细胞癌(HCC)的特征
Hepatol Int. 2016 Jul;10(4):632-9. doi: 10.1007/s12072-015-9679-0. Epub 2015 Nov 11.
3
Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.非肝硬化非酒精性脂肪性肝病患者肝细胞癌的特征和结局。
Liver Int. 2019 Jun;39(6):1098-1108. doi: 10.1111/liv.14087. Epub 2019 Mar 29.
4
Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.非肝硬化非酒精性脂肪性肝病和代谢综合征背景下的肝细胞癌:美国的经验
Dig Dis Sci. 2015 Oct;60(10):3142-8. doi: 10.1007/s10620-015-3821-7. Epub 2015 Aug 7.
5
Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands.肝硬化肝脏与非肝硬化肝脏中的肝细胞癌:来自荷兰一个大型队列的结果。
Eur J Gastroenterol Hepatol. 2016 Mar;28(3):352-9. doi: 10.1097/MEG.0000000000000527.
6
The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.非酒精性脂肪性肝病中肝细胞癌的故事:从流行病学、发病机制到预防与治疗。
Liver Int. 2016 Mar;36(3):317-24. doi: 10.1111/liv.13031. Epub 2015 Dec 25.
7
The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.非酒精性脂肪性肝病无肝硬化患者肝细胞癌的特征和危险因素。
J Gastroenterol Hepatol. 2020 May;35(5):862-869. doi: 10.1111/jgh.14867. Epub 2019 Dec 3.
8
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.非酒精性脂肪性肝病、代谢风险因素与肝细胞癌:一个悬而未决的问题。
World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103.
9
Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.伴有非酒精性脂肪性肝病/非酒精性脂肪性肝炎的丙型肝炎病毒相关肝硬化中的肝细胞癌的特殊组织学变异型:脂肪性肝炎相关肝细胞癌。
Am J Surg Pathol. 2010 Nov;34(11):1630-6. doi: 10.1097/PAS.0b013e3181f31caa.
10
Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study.无肝硬化患者肝细胞癌的特征、病因和趋势:美国多中心研究。
Aliment Pharmacol Ther. 2019 Oct;50(7):809-821. doi: 10.1111/apt.15464. Epub 2019 Sep 1.

引用本文的文献

1
Comparison Between Transient Elastography and Point Shear Wave Elastography in the Assessment of Liver Fibrosis According to the Grade of Liver Steatosis.根据肝脂肪变性程度比较瞬时弹性成像和点剪切波弹性成像在评估肝纤维化中的应用
J Clin Med. 2025 Aug 1;14(15):5417. doi: 10.3390/jcm14155417.
2
Hepatocellular carcinoma in patients without cirrhosis.无肝硬化患者的肝细胞癌
World J Gastroenterol. 2025 Jun 21;31(23):107100. doi: 10.3748/wjg.v31.i23.107100.
3
Factors Relating to Tumor Size and Survival in Patients with Hepatocellular Carcinoma: Significance of Platelet-Lymphocyte Ratio, Portal Vein Thrombosis, and Albumin.肝细胞癌患者肿瘤大小与生存的相关因素:血小板-淋巴细胞比值、门静脉血栓形成及白蛋白的意义
Oncology. 2025 Apr 8:1-11. doi: 10.1159/000545636.
4
Biomarker Discovery in Liver Disease Using Untargeted Metabolomics in Plasma and Saliva.基于血浆和唾液的非靶向代谢组学在肝脏疾病中生物标志物的发现
Int J Mol Sci. 2024 Sep 21;25(18):10144. doi: 10.3390/ijms251810144.
5
Oncogenic plasmid DNA and liver injury agent dictates liver cancer development in a mouse model.致癌质粒 DNA 和肝损伤剂决定小鼠模型中的肝癌发展。
Clin Sci (Lond). 2024 Oct 2;138(19):1227-1248. doi: 10.1042/CS20240560.
6
Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress.肿瘤相关巨噬细胞在肝细胞癌抗PD-1/PD-L1免疫治疗中的研究进展
Front Pharmacol. 2024 Jun 18;15:1382256. doi: 10.3389/fphar.2024.1382256. eCollection 2024.
7
Incidence and Clinical Features of Hepatitis C Virus-associated Hepatocellular Carcinoma Patients without Liver Cirrhosis in Hepatitis B Virus-endemic Area.乙肝病毒流行地区非肝硬化的丙型肝炎病毒相关肝细胞癌患者的发病率及临床特征
J Liver Cancer. 2021 Mar;21(1):34-44. doi: 10.17998/jlc.21.1.34. Epub 2021 Mar 31.
8
An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians.聚焦非肝硬化性非酒精性脂肪性肝病患者的肝细胞癌监测概述:医师面临的一项挑战
Biomedicines. 2023 Feb 16;11(2):586. doi: 10.3390/biomedicines11020586.
9
Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis.非酒精性脂肪性肝炎相关肝硬化外的肝细胞癌。
World J Gastroenterol. 2023 Jan 14;29(2):343-356. doi: 10.3748/wjg.v29.i2.343.
10
Long-Term Survival and Curative-Intent Treatment in Hepatitis B or C Virus-Associated Hepatocellular Carcinoma Patients Diagnosed during Screening.筛查诊断出的乙肝或丙肝病毒相关肝细胞癌患者的长期生存及根治性治疗
Biology (Basel). 2022 Nov 1;11(11):1597. doi: 10.3390/biology11111597.

本文引用的文献

1
From NAFLD in clinical practice to answers from guidelines.从临床实践中的非酒精性脂肪性肝病到指南中的答案。
J Hepatol. 2013 Oct;59(4):859-71. doi: 10.1016/j.jhep.2013.05.044. Epub 2013 Jun 7.
2
Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome.根据代谢综合征的诊断标准识别非酒精性脂肪性肝病患者。
World J Gastroenterol. 2012 Apr 7;18(13):1508-16. doi: 10.3748/wjg.v18.i13.1508.
3
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.非酒精性脂肪性肝病的诊断与管理:美国肝病研究协会、美国胃肠病学会和美国胃肠病协会实践指南
Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762.
4
Severity of fatty liver on ultrasound correlates with metabolic and cardiovascular risk.超声检查中脂肪肝的严重程度与代谢和心血管风险相关。
Kaohsiung J Med Sci. 2012 Mar;28(3):151-60. doi: 10.1016/j.kjms.2011.10.005. Epub 2012 Jan 17.
5
Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.非酒精性脂肪性肝病相关肝细胞癌:一种新出现的威胁。
J Hepatol. 2012 Jun;56(6):1384-91. doi: 10.1016/j.jhep.2011.10.027. Epub 2012 Feb 9.
6
Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma.非酒精性脂肪性肝病相关肝细胞癌的临床特征。
Hepatobiliary Pancreat Dis Int. 2012 Feb;11(1):18-27. doi: 10.1016/s1499-3872(11)60120-3.
7
Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients.非酒精性脂肪性肝病或丙型肝炎导致的老年日本患者慢性肝病恶性肿瘤的差异。
Hepatol Res. 2012 Mar;42(3):264-72. doi: 10.1111/j.1872-034X.2011.00915.x. Epub 2011 Dec 19.
8
Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.日本非酒精性脂肪性肝病患者发生肝细胞癌的大规模长期随访研究。
Am J Gastroenterol. 2012 Feb;107(2):253-61. doi: 10.1038/ajg.2011.327. Epub 2011 Oct 18.
9
Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?非酒精性脂肪性肝炎相关肝细胞癌:流行趋势的有力证据?
Hepatol Res. 2012 Jan;42(1):1-14. doi: 10.1111/j.1872-034X.2011.00872.x. Epub 2011 Sep 15.
10
Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis.糖尿病与肝细胞癌风险:系统评价和荟萃分析。
Diabetes Metab Res Rev. 2012 Feb;28(2):109-22. doi: 10.1002/dmrr.1291.

肝硬化和非肝硬化非酒精性脂肪性肝病中肝细胞癌的特征

Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease.

作者信息

Leung Christopher, Yeoh Sern Wei, Patrick Desmond, Ket Shara, Marion Kaye, Gow Paul, Angus Peter W

机构信息

Christopher Leung, Sern Wei Yeoh, Desmond Patrick, Shara Ket, Paul Gow, Peter W Angus, Liver Transplant Unit, Austin Hospital, Heidelberg, Victoria 3084, Australia.

出版信息

World J Gastroenterol. 2015 Jan 28;21(4):1189-96. doi: 10.3748/wjg.v21.i4.1189.

DOI:10.3748/wjg.v21.i4.1189
PMID:25632192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4306163/
Abstract

AIM

To determine characteristics and prognostic predictors of patients with hepatocellular carcinoma (HCC) in association with non-alcoholic fatty liver disease (NAFLD).

METHODS

We reviewed the records of all patients with NAFLD associated HCC between 2000 and 2012. Data collected included demographics; histology; presence or absence of cirrhosis, size and number of HCC, alpha-fetoprotein, body mass index (BMI), and the presence of diabetes, hypertension, or dyslipidaemia.

RESULTS

Fifty-four patients with NAFLD associated HCC were identified. Mean age was 64 years with 87% male. Fifteen percent (8/54) were not cirrhotic. 11%, 24% and 50% had a BMI of <25 kg/m2, 25-29 kg/m2 and ≥30 kg/m2 respectively. Fifty-nine percent were diabetic, 44% hypertensive and 26% hyperlipidaemic. Thirty-four percent of the patients had ≤1 of these risk factors. Non-cirrhotics had a significantly larger mean tumour diameter at diagnosis than cirrhotics (P=0.041). Multivariate analysis did not identify any other patient characteristics that predicted the size or number of HCC.

CONCLUSION

HCC can develop in NAFLD without cirrhosis. At diagnosis such tumours are larger than those in cirrhotics, conferring a poorer prognosis.

摘要

目的

确定肝细胞癌(HCC)合并非酒精性脂肪性肝病(NAFLD)患者的特征及预后预测因素。

方法

我们回顾了2000年至2012年间所有NAFLD相关HCC患者的记录。收集的数据包括人口统计学资料;组织学;有无肝硬化、HCC的大小和数量、甲胎蛋白、体重指数(BMI)以及糖尿病、高血压或血脂异常的情况。

结果

共确定了54例NAFLD相关HCC患者。平均年龄为64岁,男性占87%。15%(8/54)无肝硬化。BMI<25kg/m²、25 - 29kg/m²和≥30kg/m²的患者分别占11%、24%和50%。59%患有糖尿病,44%患有高血压,26%患有血脂异常。34%的患者具有≤1种这些危险因素。非肝硬化患者诊断时的平均肿瘤直径显著大于肝硬化患者(P = 0.041)。多因素分析未发现其他可预测HCC大小或数量的患者特征。

结论

NAFLD患者无肝硬化时也可发生HCC。诊断时此类肿瘤比肝硬化患者的肿瘤更大,预后更差。